NO20052106L - N-substituerte-2-oksodihydropyridinderivater. - Google Patents
N-substituerte-2-oksodihydropyridinderivater.Info
- Publication number
- NO20052106L NO20052106L NO20052106A NO20052106A NO20052106L NO 20052106 L NO20052106 L NO 20052106L NO 20052106 A NO20052106 A NO 20052106A NO 20052106 A NO20052106 A NO 20052106A NO 20052106 L NO20052106 L NO 20052106L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- alkylamino
- alkylcarbamoyl
- lower alkyl
- hydroxy
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000003282 alkyl amino group Chemical group 0.000 abstract 6
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 229940119154 Neuropeptide Y receptor antagonist Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Forbindelse med formel (I): hvori Ar1 og Ar2 er uavhengig aryl eller heteroaryl, en hvilken som helst av disse er eventuelt substituert med en substituent utvalgt fra gruppen som består av cyano, halogen, nitro, lavere alkyl, halo-lavere alkyl, hydroksy-lavere alkyl, cyklo-lavere alkyl, cyklo(lavere alkyl)-lavere alkyl, lavere alkenyl, lavere alkylamino, di-lavere alkylamino, lavere alkanoylamino, lavere alkylsulfonylamino, arylsulfonylamino, hydroksy, lavere alkoksy, halo-lavere alkoksy, aryloksy, heteroaryloksy, lavere alkyltio, karboksyl, formyl, lavere alkanoyl, lavere alkoksykarbonyl, karbamoyl, lavere alkylkarbamoyl, di-lavere alkylkarbamoyl, lavere alkylsulfonyl, arylsulfonyl, aryl og heteroaryl; R1 og R2 er uavhengig lavere alkyl, cyklo-lavere alkyl, cyklo(lavere alkyl)-lavere alkyl eller lavere alkoksy, hvor en hvilken som helst av disse er eventuelt substituert med en substituent utvalgt fra gruppen som består av halogen, lavere alkylamino, di-lavere alkylamino, lavere alkanoylamino, hydroksy, lavere alkoksy, formyl, lavere alkoksykarbonyl, lavere alkylkarbamoyl og di-lavere alkylkarbamoyl; R3 , R4 og R5 er uavhengig hydrogen, cyano, halogen eller hydroksy, eller lavere alkyl, lavere alkoksy eller lavere alkyltio, hvor de tre siste gruppene eventuelt er substituert med en substituent utvalgt fra gruppen som består av halogen, lavere alkylamino, dilavere alkylamino, lavere alkanoylamino, hydroksy, lavere alkoksy, formyl, lavere alkoksykarbonyl, lavere alkylkarbamoyl og di-lavere alkylkarbamoyl), eller et salt eller ester derav er anvendelig som et neuropeptid Y reseptor antagonist middel og er også anvendelig som et middel for behandling av bulimi, fedme eller diabetes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002287015 | 2002-09-30 | ||
| JP2002353202 | 2002-12-05 | ||
| PCT/JP2003/012290 WO2004031175A2 (en) | 2002-09-30 | 2003-09-25 | N-substituted-2-oxodihydropyridine derivatives as npy antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20052106L true NO20052106L (no) | 2005-04-29 |
Family
ID=32072466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052106A NO20052106L (no) | 2002-09-30 | 2005-04-29 | N-substituerte-2-oksodihydropyridinderivater. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6869966B2 (no) |
| EP (1) | EP1546133B1 (no) |
| KR (1) | KR20050059217A (no) |
| CN (1) | CN100528864C (no) |
| AR (1) | AR041374A1 (no) |
| AT (1) | ATE461191T1 (no) |
| AU (1) | AU2003273522B2 (no) |
| BR (1) | BR0314965A (no) |
| CA (2) | CA2497237C (no) |
| DE (1) | DE60331751D1 (no) |
| MX (1) | MXPA05003293A (no) |
| NO (1) | NO20052106L (no) |
| PE (1) | PE20050087A1 (no) |
| PL (1) | PL376475A1 (no) |
| RU (1) | RU2005113310A (no) |
| TW (1) | TW200407138A (no) |
| WO (1) | WO2004031175A2 (no) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242566A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| MXPA06001601A (es) * | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) * | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| FR2861300B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861301B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR2861302A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN102127057A (zh) * | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| WO2005118555A1 (en) * | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| EP1828192B1 (en) * | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| SI1931350T2 (sl) * | 2005-09-14 | 2021-11-30 | Takeda Pharmaceutical Company Limited | Uporaba inhibitorjev dipeptidil peptidaze |
| SI1942898T2 (sl) * | 2005-09-14 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa |
| TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| EP1924567B1 (en) * | 2005-09-16 | 2012-08-22 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| JP2009531456A (ja) * | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | （ｒ）−３−アミノピペリジン二塩酸塩の調製 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2007115967A1 (en) * | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | Crystalline isopropanol solvate of glucokinase activator |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| EP2350010B1 (en) | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| HRP20191306T1 (hr) * | 2014-04-09 | 2019-10-18 | Genentech, Inc. | Postupak proizvodnje lijekova |
| CN112047889A (zh) * | 2018-11-30 | 2020-12-08 | 华南农业大学 | 一种n-二氟甲基杂芳烃并咪唑硫脲衍生物的制备方法 |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| EP3923933A4 (en) | 2019-02-13 | 2022-08-17 | Merck Sharp & Dohme Corp. | PYRROLIDINOREXINE RECEPTOR AGONISTS |
| EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| CN116249697A (zh) | 2020-08-18 | 2023-06-09 | 默沙东有限责任公司 | 二环庚烷吡咯烷食欲素受体激动剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH234887A (de) * | 1942-12-11 | 1944-10-31 | Ag J R Geigy | Verfahren zur Herstellung von N-Cyclohexyl-6-pyridon-3-carbonsäurediäthylamid. |
| CZ403592A3 (en) * | 1992-02-20 | 1993-12-15 | Hoechst Ag | Arylcarbonylaminoalkyldihydrooxopyridines, process of their preparation and their use |
| EP1066262A4 (en) * | 1998-03-25 | 2004-09-01 | Bristol Myers Squibb Co | IMIDAZOLONE ANOREXIGENAL AGENTS: ACYCLIC DERIVATIVES I |
| AU3412801A (en) | 2000-02-22 | 2001-09-03 | Banyu Pharma Co Ltd | Novel imidazoline compounds |
-
2003
- 2003-08-15 US US10/641,017 patent/US6869966B2/en not_active Expired - Fee Related
- 2003-09-17 TW TW092125570A patent/TW200407138A/zh unknown
- 2003-09-22 PE PE2003000968A patent/PE20050087A1/es not_active Application Discontinuation
- 2003-09-24 AR ARP030103473A patent/AR041374A1/es unknown
- 2003-09-25 EP EP03755682A patent/EP1546133B1/en not_active Expired - Lifetime
- 2003-09-25 CN CNB038233398A patent/CN100528864C/zh not_active Expired - Fee Related
- 2003-09-25 AU AU2003273522A patent/AU2003273522B2/en not_active Ceased
- 2003-09-25 RU RU2005113310/04A patent/RU2005113310A/ru not_active Application Discontinuation
- 2003-09-25 PL PL03376475A patent/PL376475A1/xx not_active Application Discontinuation
- 2003-09-25 BR BR0314965-0A patent/BR0314965A/pt not_active Application Discontinuation
- 2003-09-25 KR KR1020057005511A patent/KR20050059217A/ko not_active Withdrawn
- 2003-09-25 WO PCT/JP2003/012290 patent/WO2004031175A2/en not_active Ceased
- 2003-09-25 AT AT03755682T patent/ATE461191T1/de not_active IP Right Cessation
- 2003-09-25 CA CA2497237A patent/CA2497237C/en not_active Expired - Fee Related
- 2003-09-25 CA CA2726754A patent/CA2726754C/en not_active Expired - Fee Related
- 2003-09-25 DE DE60331751T patent/DE60331751D1/de not_active Expired - Lifetime
- 2003-09-25 MX MXPA05003293A patent/MXPA05003293A/es unknown
-
2004
- 2004-07-27 US US10/899,162 patent/US7138525B2/en not_active Expired - Fee Related
-
2005
- 2005-04-29 NO NO20052106A patent/NO20052106L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1546133B1 (en) | 2010-03-17 |
| WO2004031175A3 (en) | 2005-02-24 |
| US20040072874A1 (en) | 2004-04-15 |
| CA2726754C (en) | 2013-04-02 |
| CA2497237C (en) | 2011-03-29 |
| WO2004031175A2 (en) | 2004-04-15 |
| AR041374A1 (es) | 2005-05-11 |
| US20050009879A1 (en) | 2005-01-13 |
| BR0314965A (pt) | 2005-08-02 |
| PL376475A1 (en) | 2005-12-27 |
| CN1684954A (zh) | 2005-10-19 |
| US7138525B2 (en) | 2006-11-21 |
| AU2003273522B2 (en) | 2009-05-21 |
| DE60331751D1 (de) | 2010-04-29 |
| RU2005113310A (ru) | 2005-11-10 |
| KR20050059217A (ko) | 2005-06-17 |
| TW200407138A (en) | 2004-05-16 |
| US6869966B2 (en) | 2005-03-22 |
| AU2003273522A1 (en) | 2004-04-23 |
| PE20050087A1 (es) | 2005-02-22 |
| MXPA05003293A (es) | 2005-10-18 |
| CA2726754A1 (en) | 2004-04-15 |
| ATE461191T1 (de) | 2010-04-15 |
| CN100528864C (zh) | 2009-08-19 |
| EP1546133A2 (en) | 2005-06-29 |
| CA2497237A1 (en) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052106L (no) | N-substituerte-2-oksodihydropyridinderivater. | |
| BRPI0411365A (pt) | derivados de aminopiridina | |
| NO20066055L (no) | Pyridinderivater | |
| NO20072344L (no) | Trombineresptorantagonister. | |
| UA84878C2 (ru) | Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения | |
| NO20085176L (no) | Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter | |
| NO20072753L (no) | 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer | |
| NO20060670L (no) | N3-substituerte imidazopyridin C-kit inhibitorer | |
| NO20092033L (no) | Nye forbindelser | |
| NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
| EA200600317A1 (ru) | Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты) | |
| NO20061157L (no) | 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer | |
| NO20044995L (no) | Heterosykliske forbindelser | |
| NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
| NO20075082L (no) | Pyridin-3-karboksamidderivater som CB1-inversagonister | |
| WO2005009975A3 (en) | Benzimidazole derivatives as mek inhibitors | |
| NO20055977L (no) | Nye benzimidazolderivater | |
| NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister | |
| NO20053133L (no) | Kjemiske forbindelser. | |
| TW200643013A (en) | Pyrazoles | |
| ATE355265T1 (de) | Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren | |
| GB0402809D0 (en) | Chemical compounds | |
| ATE386012T1 (de) | Phenyloxyalkansäure-derivate als hppar aktivatore | |
| DE602004005960D1 (de) | Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten | |
| NO20080110L (no) | Benzimidazolderivativer som 5-HT6,5-HT24 |